Chongqing Zhifei Biological Products Co., Ltd. Class ASZSE: 300122

Chongqing Zhifei Biological Products Co: 2024 saw a 50%+ drop in revenue and profit, prompting a strategic focus on R&D and resilience

· Issued by Chongqing Zhifei Biological Products Co., Ltd. Class A

Revenue and net profit fell sharply in 2024 due to industry and market headwinds, with core financials down over 50% year-over-year. The company is responding with increased R&D, product innovation, and strategic partnerships to support long-term growth.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Company analysis

Earlier from Chongqing Zhifei Biological Products Co., Ltd. Class A

All Chongqing Zhifei Biological Products Co., Ltd. Class A news releases